Neurocrine Biosciences
NBIX
198 hedge funds and large institutions have $3.98B invested in Neurocrine Biosciences in 2015 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 87 increasing their positions, 52 reducing their positions, and 15 closing their positions.
226% more call options, than puts
Call options by funds: $61.7M | Put options by funds: $18.9M
167% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 15
67% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 52
18% more capital invested
Capital invested by funds: $3.38B → $3.98B (+$603M)
14% more funds holding
Funds holding: 174 → 198 (+24)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$60.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$17.8M |
| 3 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$16.9M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
+$14.8M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$12.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
-$47.3M |
| 2 |
VAM
Visium Asset Management
New York
|
-$42.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$35.1M |
| 4 |
O
OrbiMed
New York
|
-$31.3M |
| 5 |
PA
Perceptive Advisors
New York
|
-$19.4M |
NBIX Hedge Fund Activity: Q2 2015 in Review
198 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q2 2015, worth a combined $3.98B — up 18% from $3.38B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new NBIX positions and 15 closed out — a net gain of 25 holders — while 87 added to existing stakes and 52 trimmed.
The largest buyer was Vanguard Group, adding an estimated $60.2M. The largest seller was Westfield Capital Management, cutting an estimated $47.3M.
- 198 institutional investors held Neurocrine Biosciences (NBIX) as of Q2 2015, up from 174 in Q1 2015.
- Funds reported $3.98B of Neurocrine Biosciences stock for Q2 2015, up 18% quarter-over-quarter.
- 40 funds opened new Neurocrine Biosciences positions in Q2 2015 and 15 closed out, a net change of +25 holders.
- The largest Neurocrine Biosciences buyer in Q2 2015 was Vanguard Group, an estimated $60.2M added.
- The largest Neurocrine Biosciences seller in Q2 2015 was Westfield Capital Management, an estimated $47.3M sold.
Based on aggregated 13F filings for Q2 2015.